acamprosate vs tetrabenazine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and tetrabenazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Xenazine
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Tetrabenazine is a medicine used to treat chorea (uncontrollable movements) caused by Huntington's disease. It helps to reduce these movements.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Tetrabenazine is used to treat chorea, which are the involuntary, jerky movements that happen with Huntington's disease. Huntington's disease is a brain disorder that affects movement, behavior, and thinking. This medicine can help control the movements caused by this condition.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Tetrabenazine works by affecting a substance in the brain that moves other chemicals. It lowers the amount of certain chemicals, like dopamine, in the brain. This helps to control the involuntary movements (chorea) caused by Huntington's disease.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Feeling sleepy or drowsy
- • Feeling tired
- • Trouble sleeping
- • Feeling depressed
- • Feeling restless
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Death 1,216
- Depression 474
- Somnolence 451
- Fatigue 360
- Fall 314
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Tetrabenazine can increase the risk of depression and suicidal thoughts in people with Huntington's disease. If you have thoughts of harming yourself, tell your doctor right away. You should not take this medicine if you are actively suicidal or have untreated depression.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
This medicine may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine passes into breast milk, so talk to your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare tetrabenazine with
How to Read This acamprosate vs tetrabenazine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while tetrabenazine sits within the VMAT2 Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while tetrabenazine has 2,815. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or tetrabenazine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.